MacdougallI.C.Poor response to erythropoietin: practical guidelines on investigation and management.Nephrol Dial Transplant1995; 10: 607–14.
2.
AllenD.A., BreenC., YaqoobM.M., MacdougallI.C.Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: role of IFN-gamma and TNF-alpha.J Investig Med1999; 47: 204–11.
3.
CooperA.C., MikkailA., LethbridgeM.W., KemenyD.M., MacDougallI.C.Increased expression of erythropoiesis inhibiting cytokines (IFN-γ, TNF-α, IL-10 and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy.J Am Soc Nephrol2003; 14: 1776–84.
4.
MrugM., StopkaT., JulianB.A., PrchalJ.F., PrchalJ.T.Angiotensin II stimulates proliferation of normal early erythroid progenitors.J Clin Invest1997; 100: 2310–14.
5.
ColeJ., ErtoyD., LinH., SutliffR.L., EzanE., GuyeneT.T.Lack of angiotensin II-facilitated erythropoiesis causes anemia in angiotensin-converting enzyme-deficient mice.J Clin Invest2000; 106: 1391–8.
6.
MacdougallI.C.The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin.Nephrol Dial Transplant1999; 14: 1836–41.
7.
EvansW.E., McLeodH.L.Pharmacogenomics — drug disposition, drug targets and side effects.N Engl J Med2003; 348: 538–49.
SharplesE.J., VaragunamM., SinnottP.J., McCloskeyD.J., RafteryM.J., YaqoobM.M.The effect of proinflammatory cytokine gene and angiotensin-converting enzyme polymorphisms on erythropoietin requirements in patients on continuous ambulatory peritoneal dialysis.Perit Dial Int2006; 26: 64–8.
10.
RigatB., HubertC., Alhenc-GelasF., CambienF., CorvolP., SoubrierF.An insertion/deletion polymorphism in the angiotensin I converting enzyme gene accounting for half the variance of serum enzyme levels.J Clin Invest1990; 86: 1343–6.
11.
BloemL.J., ManatungaA.K., PrattJ.H.Racial difference in the relationship of an angiotensin I converting enzyme gene polymorphism to serum angiotensin I converting enzyme activity.Hypertension1996; 27: 62–6.
12.
KeavneyB., McKenzieC., ParishS., PalmerA., ClarkS., YoungmanL.Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls.Lancet2000; 355: 434–42.
13.
JacobsenP., RossingK., RossingP., TarnowL., MalletC., PoirierO.Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy.Kidney Int1998; 53: 1002–6.
14.
AndersenS., TarnowL., CambienF., RossingP., JuhlT.R., DeinumJ.Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?Kidney Int2002; 62: 192–8.
15.
HumphriesS.E., LuongL.A., OggM.S., HaweE., MillerG.J.The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men.Eur Heart J2001; 22: 2219–20.
